+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
New

Rotavirus Vaccines - Global Strategic Business Report

  • PDF Icon

    Report

  • 285 Pages
  • June 2025
  • Region: Global
  • Global Industry Analysts, Inc
  • ID: 6088763
The global market for Network Synchronization ICs was estimated at US$872.3 Million in 2024 and is projected to reach US$1.6 Billion by 2030, growing at a CAGR of 10.5% from 2024 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions. The report includes the most recent global tariff developments and how they impact the Network Synchronization ICs market.

Global Network Synchronization ICs Market - Key Trends & Drivers Summarized

Why Are Network Synchronization ICs Critical to Modern Communication Infrastructure?

Network synchronization ICs (integrated circuits) are foundational components enabling precise timing and frequency alignment across telecommunications, data centers, and industrial network systems. In a world increasingly dependent on ultra-reliable, low-latency connectivity, synchronization ICs play a pivotal role in maintaining seamless operation across diverse network elements. These chips are responsible for generating, distributing, and managing clock signals that ensure coordinated data transmission, error minimization, and interoperability across complex systems.

With the proliferation of 5G networks, optical transport systems, and distributed computing, the need for sub-microsecond timing accuracy has surged. These ICs support synchronization standards such as IEEE 1588 Precision Time Protocol (PTP), Synchronous Ethernet (SyncE), and Global Navigation Satellite System (GNSS)-based timing allowing precise coordination between base stations, routers, switches, and servers. As bandwidth-intensive applications like mobile video, cloud gaming, and industrial automation expand, the importance of reliable, jitter-free clock distribution has elevated network synchronization from a supporting function to a strategic enabler.

What Technological Advancements Are Enhancing Performance and Integration?

Modern network synchronization ICs are evolving rapidly with innovations in jitter attenuation, phase noise reduction, and multi-protocol support. Today's chips offer integrated functions such as clock synthesis, distribution, frequency translation, and redundancy management in a single footprint. This not only simplifies board design and reduces component count but also improves timing accuracy and system reliability. Ultra-low-jitter and low-power variants are increasingly being tailored for deployment in dense, power-sensitive environments like 5G small cells, edge computing nodes, and optical modules.

Support for multiple synchronization protocols within a single chip is another key development, allowing manufacturers to build systems compatible with both legacy and next-gen infrastructure. Some ICs now incorporate real-time PTP servo engines and digital phase-locked loop (DPLL) architectures to meet the stringent requirements of telecom-grade synchronization, including Class C and D timing profiles. Additionally, timing ICs with embedded security features such as signal authentication and tamper resistance are emerging in response to rising threats of timing-based cyberattacks.

Which End-Use Sectors Are Accelerating Adoption of Synchronization ICs?

The telecom industry continues to be the largest consumer of network synchronization ICs, particularly as operators build out 5G infrastructure that requires dense synchronization across thousands of cell sites. These ICs are critical in enabling time division duplexing (TDD), massive MIMO, and carrier aggregation technologies that rely on precise timing to function effectively. Mobile fronthaul and backhaul networks also depend heavily on synchronized packet flows, making timing ICs central to radio access network (RAN) architecture.

Beyond telecom, data centers are increasingly implementing synchronization ICs to optimize latency-sensitive workloads such as high-frequency trading, real-time analytics, and cloud-native applications. Industrial automation systems, including robotics and smart manufacturing lines, require tightly coordinated machine communication, making timing precision essential for safety and efficiency. Additionally, automotive applications particularly in autonomous vehicles and vehicle-to-everything (V2X) systems are incorporating timing ICs to manage synchronization across sensors, cameras, and onboard computing platforms.

What Factors Are Driving Growth in the Network Synchronization ICs Market?

The growth in the network synchronization ICs market is driven by several critical factors rooted in technological shifts, infrastructure modernization, and evolving end-user requirements. A primary growth driver is the global expansion of 5G networks, which demand ultra-precise synchronization across dense, disaggregated networks. Synchronization ICs are essential to enabling features such as low latency, higher spectral efficiency, and network slicing in next-generation mobile systems.

End-use expansion across edge computing, autonomous systems, industrial automation, and time-sensitive networking (TSN) is widening the market's application scope. The increasing reliance on software-defined networks (SDNs), network function virtualization (NFV), and distributed data environments is creating a greater need for embedded timing intelligence at the chip level. Furthermore, regulatory mandates around timing standards in telecom and power grid applications are reinforcing the need for compliance-capable timing ICs.

Advancements in packaging, integration, and low-jitter design are enabling these ICs to be deployed in compact, high-density environments, while flexible protocol support allows seamless deployment across evolving infrastructures. As industries continue to shift toward real-time, synchronized digital operations, network synchronization ICs are poised to become a linchpin in the architecture of future-ready communication and computing systems.

Key Insights:

  • Market Growth: Understand the significant growth trajectory of the Single Channel segment, which is expected to reach US$595.5 Million by 2030 with a CAGR of a 12.6%. The Dual Channel segment is also set to grow at 7.7% CAGR over the analysis period.
  • Regional Analysis: Gain insights into the U.S. market, valued at $237.6 Million in 2024, and China, forecasted to grow at an impressive 14.7% CAGR to reach $333.0 Million by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.

Why You Should Buy This Report:

  • Detailed Market Analysis: Access a thorough analysis of the Global Network Synchronization ICs Market, covering all major geographic regions and market segments.
  • Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
  • Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global Network Synchronization ICs Market.
  • Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.

Key Questions Answered:

  • How is the Global Network Synchronization ICs Market expected to evolve by 2030?
  • What are the main drivers and restraints affecting the market?
  • Which market segments will grow the most over the forecast period?
  • How will market shares for different regions and segments change by 2030?
  • Who are the leading players in the market, and what are their prospects?

Report Features:

  • Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2024 to 2030.
  • In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
  • Company Profiles: Coverage of players such as Analog Devices, Inc., Arteris, Inc., Broadcom Inc., Conemtech AB, and more.
  • Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.

Some of the 36 companies featured in this Network Synchronization ICs market report include:

  • Analog Devices, Inc.
  • Arteris, Inc.
  • Broadcom Inc.
  • Conemtech AB
  • IDT (Integrated Device Technology)
  • Infineon Technologies AG
  • Intel Corporation
  • Maxim Integrated
  • Microchip Technology Inc.
  • NXP Semiconductors N.V.
  • ON Semiconductor Corporation
  • Oscilloquartz SA
  • Qualcomm Incorporated
  • Qulsar, Inc.
  • Realtek Semiconductor Corp.
  • Renesas Electronics Corporation
  • Semtech Corporation
  • Silicon Laboratories Inc.
  • SiTime Corporation
  • Texas Instruments Incorporated

This edition integrates the latest global trade and economic shifts as of June 2025 into comprehensive market analysis. Key updates include:

  • Tariff and Trade Impact: Insights into global tariff negotiations across 180+ countries, with analysis of supply chain turbulence, sourcing disruptions, and geographic realignment. Special focus on 2025 as a pivotal year for trade tensions, including updated perspectives on the Trump-era tariffs.
  • Adjusted Forecasts and Analytics: Revised global and regional market forecasts through 2030, incorporating tariff effects, economic uncertainty, and structural changes in globalization. Includes segmentation by product, technology, type, material, distribution channel, application, and end-use, with historical analysis since 2015.
  • Strategic Market Dynamics: Evaluation of revised market prospects, regional outlooks, and key economic indicators such as population and urbanization trends.
  • Innovation & Technology Trends: Latest developments in product and process innovation, emerging technologies, and key industry drivers shaping the competitive landscape.
  • Competitive Intelligence: Updated global market share estimates for 2025, competitive positioning of major players (Strong/Active/Niche/Trivial), and refined focus on leading global brands and core players.
  • Expert Insight & Commentary: Strategic analysis from economists, trade experts, and domain specialists to contextualize market shifts and identify emerging opportunities.
  • Complimentary Update: Buyers receive a free July 2025 update with finalized tariff impacts, new trade agreement effects, revised projections, and expanded country-level coverage.

Table of Contents

I. METHODOLOGYII. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Tariff Impact on Global Supply Chain Patterns
  • Rotavirus Vaccines - Global Key Competitors Percentage Market Share in 2025 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
  • High Burden of Pediatric Diarrheal Diseases Drives Demand for Rotavirus Vaccination
  • Expanded Immunization Programs in Emerging Economies Propel Market Growth
  • World Health Organization Recommendations Strengthen the Business Case for Global Rollouts
  • Inclusion of Rotavirus Vaccines in National Immunization Schedules Expands Addressable Market
  • GAVI and UNICEF Funding Initiatives Generate Access Opportunities in Low-Income Regions
  • Advancements in Cold Chain Logistics Sustain Growth in Global Distribution
  • Rising Awareness Campaigns Around Infant Health Spur Vaccine Adoption
  • Improved Efficacy and Longer Duration of Protection Drive Preference for New Formulations
  • Ongoing Research on Combination Vaccines Throws the Spotlight on Product Innovation
  • Efforts to Reduce Child Mortality Rates Reinforce Market Demand
  • Entry of Low-Cost Manufacturers Boosts Supply in Price-Sensitive Markets
  • Regulatory Approvals of New Vaccine Variants Accelerate Market Penetration
  • Public-Private Partnerships Enhance Vaccine Delivery Infrastructure
  • Surveillance Data and Disease Burden Analytics Drive Policy and Procurement Decisions
  • Pandemic-Driven Focus on Immunization Resilience Creates Opportunities for Vaccine Market Expansion
4. GLOBAL MARKET PERSPECTIVE
  • Table 1: World Rotavirus Vaccines Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
  • Table 2: World Recent Past, Current & Future Analysis for Rotavirus Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • Table 3: World Historic Review for Rotavirus Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • Table 4: World 15-Year Perspective for Rotavirus Vaccines by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
  • Table 5: World Recent Past, Current & Future Analysis for Rotarix by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • Table 6: World Historic Review for Rotarix by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • Table 7: World 15-Year Perspective for Rotarix by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • Table 8: World Recent Past, Current & Future Analysis for Rotateq by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • Table 9: World Historic Review for Rotateq by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • Table 10: World 15-Year Perspective for Rotateq by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • Table 11: World Recent Past, Current & Future Analysis for Rotavin-M1 by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • Table 12: World Historic Review for Rotavin-M1 by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • Table 13: World 15-Year Perspective for Rotavin-M1 by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • Table 14: World Recent Past, Current & Future Analysis for Lanzhou Lamb by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • Table 15: World Historic Review for Lanzhou Lamb by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • Table 16: World 15-Year Perspective for Lanzhou Lamb by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • Table 17: World Recent Past, Current & Future Analysis for Other Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • Table 18: World Historic Review for Other Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • Table 19: World 15-Year Perspective for Other Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • Table 20: World Recent Past, Current & Future Analysis for Hospitals & Clinics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • Table 21: World Historic Review for Hospitals & Clinics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • Table 22: World 15-Year Perspective for Hospitals & Clinics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • Table 23: World Recent Past, Current & Future Analysis for Academic & Research by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • Table 24: World Historic Review for Academic & Research by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • Table 25: World 15-Year Perspective for Academic & Research by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • Table 26: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • Table 27: World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • Table 28: World 15-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
III. MARKET ANALYSIS
UNITED STATES
  • Rotavirus Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
  • Table 29: USA Recent Past, Current & Future Analysis for Rotavirus Vaccines by Type - Rotarix, Rotateq, Rotavin-M1, Lanzhou Lamb and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • Table 30: USA Historic Review for Rotavirus Vaccines by Type - Rotarix, Rotateq, Rotavin-M1, Lanzhou Lamb and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • Table 31: USA 15-Year Perspective for Rotavirus Vaccines by Type - Percentage Breakdown of Value Sales for Rotarix, Rotateq, Rotavin-M1, Lanzhou Lamb and Other Types for the Years 2015, 2025 & 2030
  • Table 32: USA Recent Past, Current & Future Analysis for Rotavirus Vaccines by End-Use - Hospitals & Clinics, Academic & Research and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • Table 33: USA Historic Review for Rotavirus Vaccines by End-Use - Hospitals & Clinics, Academic & Research and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • Table 34: USA 15-Year Perspective for Rotavirus Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Academic & Research and Other End-Uses for the Years 2015, 2025 & 2030
CANADA
  • Table 35: Canada Recent Past, Current & Future Analysis for Rotavirus Vaccines by Type - Rotarix, Rotateq, Rotavin-M1, Lanzhou Lamb and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • Table 36: Canada Historic Review for Rotavirus Vaccines by Type - Rotarix, Rotateq, Rotavin-M1, Lanzhou Lamb and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • Table 37: Canada 15-Year Perspective for Rotavirus Vaccines by Type - Percentage Breakdown of Value Sales for Rotarix, Rotateq, Rotavin-M1, Lanzhou Lamb and Other Types for the Years 2015, 2025 & 2030
  • Table 38: Canada Recent Past, Current & Future Analysis for Rotavirus Vaccines by End-Use - Hospitals & Clinics, Academic & Research and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • Table 39: Canada Historic Review for Rotavirus Vaccines by End-Use - Hospitals & Clinics, Academic & Research and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • Table 40: Canada 15-Year Perspective for Rotavirus Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Academic & Research and Other End-Uses for the Years 2015, 2025 & 2030
JAPAN
  • Rotavirus Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
  • Table 41: Japan Recent Past, Current & Future Analysis for Rotavirus Vaccines by Type - Rotarix, Rotateq, Rotavin-M1, Lanzhou Lamb and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • Table 42: Japan Historic Review for Rotavirus Vaccines by Type - Rotarix, Rotateq, Rotavin-M1, Lanzhou Lamb and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • Table 43: Japan 15-Year Perspective for Rotavirus Vaccines by Type - Percentage Breakdown of Value Sales for Rotarix, Rotateq, Rotavin-M1, Lanzhou Lamb and Other Types for the Years 2015, 2025 & 2030
  • Table 44: Japan Recent Past, Current & Future Analysis for Rotavirus Vaccines by End-Use - Hospitals & Clinics, Academic & Research and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • Table 45: Japan Historic Review for Rotavirus Vaccines by End-Use - Hospitals & Clinics, Academic & Research and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • Table 46: Japan 15-Year Perspective for Rotavirus Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Academic & Research and Other End-Uses for the Years 2015, 2025 & 2030
CHINA
  • Rotavirus Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
  • Table 47: China Recent Past, Current & Future Analysis for Rotavirus Vaccines by Type - Rotarix, Rotateq, Rotavin-M1, Lanzhou Lamb and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • Table 48: China Historic Review for Rotavirus Vaccines by Type - Rotarix, Rotateq, Rotavin-M1, Lanzhou Lamb and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • Table 49: China 15-Year Perspective for Rotavirus Vaccines by Type - Percentage Breakdown of Value Sales for Rotarix, Rotateq, Rotavin-M1, Lanzhou Lamb and Other Types for the Years 2015, 2025 & 2030
  • Table 50: China Recent Past, Current & Future Analysis for Rotavirus Vaccines by End-Use - Hospitals & Clinics, Academic & Research and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • Table 51: China Historic Review for Rotavirus Vaccines by End-Use - Hospitals & Clinics, Academic & Research and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • Table 52: China 15-Year Perspective for Rotavirus Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Academic & Research and Other End-Uses for the Years 2015, 2025 & 2030
EUROPE
  • Rotavirus Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
  • Table 53: Europe Recent Past, Current & Future Analysis for Rotavirus Vaccines by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • Table 54: Europe Historic Review for Rotavirus Vaccines by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • Table 55: Europe 15-Year Perspective for Rotavirus Vaccines by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
  • Table 56: Europe Recent Past, Current & Future Analysis for Rotavirus Vaccines by Type - Rotarix, Rotateq, Rotavin-M1, Lanzhou Lamb and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • Table 57: Europe Historic Review for Rotavirus Vaccines by Type - Rotarix, Rotateq, Rotavin-M1, Lanzhou Lamb and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • Table 58: Europe 15-Year Perspective for Rotavirus Vaccines by Type - Percentage Breakdown of Value Sales for Rotarix, Rotateq, Rotavin-M1, Lanzhou Lamb and Other Types for the Years 2015, 2025 & 2030
  • Table 59: Europe Recent Past, Current & Future Analysis for Rotavirus Vaccines by End-Use - Hospitals & Clinics, Academic & Research and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • Table 60: Europe Historic Review for Rotavirus Vaccines by End-Use - Hospitals & Clinics, Academic & Research and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • Table 61: Europe 15-Year Perspective for Rotavirus Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Academic & Research and Other End-Uses for the Years 2015, 2025 & 2030
FRANCE
  • Rotavirus Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
  • Table 62: France Recent Past, Current & Future Analysis for Rotavirus Vaccines by Type - Rotarix, Rotateq, Rotavin-M1, Lanzhou Lamb and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • Table 63: France Historic Review for Rotavirus Vaccines by Type - Rotarix, Rotateq, Rotavin-M1, Lanzhou Lamb and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • Table 64: France 15-Year Perspective for Rotavirus Vaccines by Type - Percentage Breakdown of Value Sales for Rotarix, Rotateq, Rotavin-M1, Lanzhou Lamb and Other Types for the Years 2015, 2025 & 2030
  • Table 65: France Recent Past, Current & Future Analysis for Rotavirus Vaccines by End-Use - Hospitals & Clinics, Academic & Research and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • Table 66: France Historic Review for Rotavirus Vaccines by End-Use - Hospitals & Clinics, Academic & Research and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • Table 67: France 15-Year Perspective for Rotavirus Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Academic & Research and Other End-Uses for the Years 2015, 2025 & 2030
GERMANY
  • Rotavirus Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
  • Table 68: Germany Recent Past, Current & Future Analysis for Rotavirus Vaccines by Type - Rotarix, Rotateq, Rotavin-M1, Lanzhou Lamb and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • Table 69: Germany Historic Review for Rotavirus Vaccines by Type - Rotarix, Rotateq, Rotavin-M1, Lanzhou Lamb and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • Table 70: Germany 15-Year Perspective for Rotavirus Vaccines by Type - Percentage Breakdown of Value Sales for Rotarix, Rotateq, Rotavin-M1, Lanzhou Lamb and Other Types for the Years 2015, 2025 & 2030
  • Table 71: Germany Recent Past, Current & Future Analysis for Rotavirus Vaccines by End-Use - Hospitals & Clinics, Academic & Research and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • Table 72: Germany Historic Review for Rotavirus Vaccines by End-Use - Hospitals & Clinics, Academic & Research and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • Table 73: Germany 15-Year Perspective for Rotavirus Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Academic & Research and Other End-Uses for the Years 2015, 2025 & 2030
ITALY
  • Table 74: Italy Recent Past, Current & Future Analysis for Rotavirus Vaccines by Type - Rotarix, Rotateq, Rotavin-M1, Lanzhou Lamb and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • Table 75: Italy Historic Review for Rotavirus Vaccines by Type - Rotarix, Rotateq, Rotavin-M1, Lanzhou Lamb and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • Table 76: Italy 15-Year Perspective for Rotavirus Vaccines by Type - Percentage Breakdown of Value Sales for Rotarix, Rotateq, Rotavin-M1, Lanzhou Lamb and Other Types for the Years 2015, 2025 & 2030
  • Table 77: Italy Recent Past, Current & Future Analysis for Rotavirus Vaccines by End-Use - Hospitals & Clinics, Academic & Research and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • Table 78: Italy Historic Review for Rotavirus Vaccines by End-Use - Hospitals & Clinics, Academic & Research and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • Table 79: Italy 15-Year Perspective for Rotavirus Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Academic & Research and Other End-Uses for the Years 2015, 2025 & 2030
UNITED KINGDOM
  • Rotavirus Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
  • Table 80: UK Recent Past, Current & Future Analysis for Rotavirus Vaccines by Type - Rotarix, Rotateq, Rotavin-M1, Lanzhou Lamb and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • Table 81: UK Historic Review for Rotavirus Vaccines by Type - Rotarix, Rotateq, Rotavin-M1, Lanzhou Lamb and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • Table 82: UK 15-Year Perspective for Rotavirus Vaccines by Type - Percentage Breakdown of Value Sales for Rotarix, Rotateq, Rotavin-M1, Lanzhou Lamb and Other Types for the Years 2015, 2025 & 2030
  • Table 83: UK Recent Past, Current & Future Analysis for Rotavirus Vaccines by End-Use - Hospitals & Clinics, Academic & Research and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • Table 84: UK Historic Review for Rotavirus Vaccines by End-Use - Hospitals & Clinics, Academic & Research and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • Table 85: UK 15-Year Perspective for Rotavirus Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Academic & Research and Other End-Uses for the Years 2015, 2025 & 2030
SPAIN
  • Table 86: Spain Recent Past, Current & Future Analysis for Rotavirus Vaccines by Type - Rotarix, Rotateq, Rotavin-M1, Lanzhou Lamb and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • Table 87: Spain Historic Review for Rotavirus Vaccines by Type - Rotarix, Rotateq, Rotavin-M1, Lanzhou Lamb and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • Table 88: Spain 15-Year Perspective for Rotavirus Vaccines by Type - Percentage Breakdown of Value Sales for Rotarix, Rotateq, Rotavin-M1, Lanzhou Lamb and Other Types for the Years 2015, 2025 & 2030
  • Table 89: Spain Recent Past, Current & Future Analysis for Rotavirus Vaccines by End-Use - Hospitals & Clinics, Academic & Research and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • Table 90: Spain Historic Review for Rotavirus Vaccines by End-Use - Hospitals & Clinics, Academic & Research and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • Table 91: Spain 15-Year Perspective for Rotavirus Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Academic & Research and Other End-Uses for the Years 2015, 2025 & 2030
RUSSIA
  • Table 92: Russia Recent Past, Current & Future Analysis for Rotavirus Vaccines by Type - Rotarix, Rotateq, Rotavin-M1, Lanzhou Lamb and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • Table 93: Russia Historic Review for Rotavirus Vaccines by Type - Rotarix, Rotateq, Rotavin-M1, Lanzhou Lamb and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • Table 94: Russia 15-Year Perspective for Rotavirus Vaccines by Type - Percentage Breakdown of Value Sales for Rotarix, Rotateq, Rotavin-M1, Lanzhou Lamb and Other Types for the Years 2015, 2025 & 2030
  • Table 95: Russia Recent Past, Current & Future Analysis for Rotavirus Vaccines by End-Use - Hospitals & Clinics, Academic & Research and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • Table 96: Russia Historic Review for Rotavirus Vaccines by End-Use - Hospitals & Clinics, Academic & Research and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • Table 97: Russia 15-Year Perspective for Rotavirus Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Academic & Research and Other End-Uses for the Years 2015, 2025 & 2030
REST OF EUROPE
  • Table 98: Rest of Europe Recent Past, Current & Future Analysis for Rotavirus Vaccines by Type - Rotarix, Rotateq, Rotavin-M1, Lanzhou Lamb and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • Table 99: Rest of Europe Historic Review for Rotavirus Vaccines by Type - Rotarix, Rotateq, Rotavin-M1, Lanzhou Lamb and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • Table 100: Rest of Europe 15-Year Perspective for Rotavirus Vaccines by Type - Percentage Breakdown of Value Sales for Rotarix, Rotateq, Rotavin-M1, Lanzhou Lamb and Other Types for the Years 2015, 2025 & 2030
  • Table 101: Rest of Europe Recent Past, Current & Future Analysis for Rotavirus Vaccines by End-Use - Hospitals & Clinics, Academic & Research and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • Table 102: Rest of Europe Historic Review for Rotavirus Vaccines by End-Use - Hospitals & Clinics, Academic & Research and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • Table 103: Rest of Europe 15-Year Perspective for Rotavirus Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Academic & Research and Other End-Uses for the Years 2015, 2025 & 2030
ASIA-PACIFIC
  • Rotavirus Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
  • Table 104: Asia-Pacific Recent Past, Current & Future Analysis for Rotavirus Vaccines by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • Table 105: Asia-Pacific Historic Review for Rotavirus Vaccines by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • Table 106: Asia-Pacific 15-Year Perspective for Rotavirus Vaccines by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
  • Table 107: Asia-Pacific Recent Past, Current & Future Analysis for Rotavirus Vaccines by Type - Rotarix, Rotateq, Rotavin-M1, Lanzhou Lamb and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • Table 108: Asia-Pacific Historic Review for Rotavirus Vaccines by Type - Rotarix, Rotateq, Rotavin-M1, Lanzhou Lamb and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • Table 109: Asia-Pacific 15-Year Perspective for Rotavirus Vaccines by Type - Percentage Breakdown of Value Sales for Rotarix, Rotateq, Rotavin-M1, Lanzhou Lamb and Other Types for the Years 2015, 2025 & 2030
  • Table 110: Asia-Pacific Recent Past, Current & Future Analysis for Rotavirus Vaccines by End-Use - Hospitals & Clinics, Academic & Research and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • Table 111: Asia-Pacific Historic Review for Rotavirus Vaccines by End-Use - Hospitals & Clinics, Academic & Research and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • Table 112: Asia-Pacific 15-Year Perspective for Rotavirus Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Academic & Research and Other End-Uses for the Years 2015, 2025 & 2030
AUSTRALIA
  • Rotavirus Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
INDIA
  • Rotavirus Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
SOUTH KOREAREST OF ASIA-PACIFIC
LATIN AMERICA
  • Rotavirus Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
ARGENTINABRAZILMEXICOREST OF LATIN AMERICA
MIDDLE EAST
  • Rotavirus Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
IRANISRAELSAUDI ARABIAUNITED ARAB EMIRATESREST OF MIDDLE EAST
AFRICA
  • Rotavirus Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
IV. COMPETITION

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Analog Devices, Inc.
  • Arteris, Inc.
  • Broadcom Inc.
  • Conemtech AB
  • IDT (Integrated Device Technology)
  • Infineon Technologies AG
  • Intel Corporation
  • Maxim Integrated
  • Microchip Technology Inc.
  • NXP Semiconductors N.V.
  • ON Semiconductor Corporation
  • Oscilloquartz SA
  • Qualcomm Incorporated
  • Qulsar, Inc.
  • Realtek Semiconductor Corp.
  • Renesas Electronics Corporation
  • Semtech Corporation
  • Silicon Laboratories Inc.
  • SiTime Corporation
  • Texas Instruments Incorporated

Table Information